A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL
Status:
Recruiting
Trial end date:
2022-10-01
Target enrollment:
Participant gender:
Summary
To compare efficacy between zanubrutinib versus bendamustine and rituximab in patients with
previously untreated CLL/SLL, as measured by progression free survival.